Business Context and Reporting Period
This Form 8-K was filed by Amedica Corporation on November 10, 2015. The report discloses a significant corporate event regarding the company's clinical trial progress. Note: The request metadata references "Sintx Technologies, Inc.," but the filing text explicitly identifies the registrant as Amedica Corporation.
Key Financial Metrics
This filing is a Current Report (Form 8-K) focused on a specific event and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The material change reported is the submission of clinical data to the U.S. Food and Drug Administration (FDA):
- Event: Submission of 24-month clinical data outcomes from the CASCADE study.
- Study Design: A blinded, randomized clinical trial.
- Comparison: Outcomes of Amedica's composite silicon nitride devices (with an integrated core of cancellous structured ceramic, CsC) versus the existing standard of PEEK (polyether ether ketone plastic) spacers filled with bone autograft.
- Application: Cervical fusion procedures.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, future outlook projections, or a detailed risk factor analysis. The primary focus is the regulatory milestone of submitting the CASCADE study data. The press release attached as Exhibit 99.1 is incorporated by reference for further details on the study outcomes.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) to understand the specific results of the CASCADE study.
- Confirm the FDA's subsequent review status and any potential regulatory actions following the data submission.
- Review the company's most recent 10-K or 10-Q filings for actual financial performance metrics, as this 8-K contains none.
- Clarify the relationship between the request metadata (Sintx Technologies) and the filing registrant (Amedica Corporation) to ensure correct entity tracking.